FDG PET/CT in follow UP patients with colorectal carcinoma after adjuvant chemotherapy

Abstract Background 18F-2-fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography-computed tomography (PET-CT) is a method of imaging that assesses and measures metabolic avidity in cancer cells, acting as a proxy for underlying cellular activity and vitality and so providing anatomic and me...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Remon Zaher Elia, Rafik Abdelazem Elbastawessy, Hanaa Abdelkader Abdelmgeguid, Ahmed Mohamed Bassiouny
Format: article
Langue:EN
Publié: SpringerOpen 2021
Sujets:
Accès en ligne:https://doaj.org/article/6be02219bbee4a4891037b8bb6c43ac9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
id oai:doaj.org-article:6be02219bbee4a4891037b8bb6c43ac9
record_format dspace
spelling oai:doaj.org-article:6be02219bbee4a4891037b8bb6c43ac92021-12-05T12:17:28ZFDG PET/CT in follow UP patients with colorectal carcinoma after adjuvant chemotherapy10.1186/s43055-021-00655-22090-4762https://doaj.org/article/6be02219bbee4a4891037b8bb6c43ac92021-11-01T00:00:00Zhttps://doi.org/10.1186/s43055-021-00655-2https://doaj.org/toc/2090-4762Abstract Background 18F-2-fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography-computed tomography (PET-CT) is a method of imaging that assesses and measures metabolic avidity in cancer cells, acting as a proxy for underlying cellular activity and vitality and so providing anatomic and metabolic information. 18F-FDG PET-CT is beneficial for detecting local recurrence, distant metastases, and monitoring tumor viability after chemotherapy and radiotherapy in patients with colorectal cancer. Strict adherence to set protocols, technological processes, and good patient preparation are essential to produce the greatest results. The goal of the trial was to see how useful PET/CT was in following up on patients who had resected colorectal cancer and had completed adjuvant chemotherapy rounds. Results In this study, PET/CT early detected hepatic deposits, pulmonary masses, bone deposits, and sizable LNs. PET/CT provided useful information and had a considerable impact on disease management, enabling the detection of recurrent disease as early as possible with high accuracy in assessment of therapeutic response. It detected viable residual tumor cells in operative bed scar, small metabolically active LNs, hepatic focal lesions, peritoneal deposits, pulmonary secondaries, and bone deposits avoiding unnecessary surgeries. Conclusion Because of its high accuracy in detection and capacity to identify recurrent illness, FDG-PET-CT imaging is effective in evaluating post-therapeutic colorectal cancer patients with suspected tumor recurrence or distant metastases.Remon Zaher EliaRafik Abdelazem ElbastawessyHanaa Abdelkader AbdelmgeguidAhmed Mohamed BassiounySpringerOpenarticleFDG PET/CTColorectal carcinomaAdjuvant chemotherapyMedical physics. Medical radiology. Nuclear medicineR895-920ENThe Egyptian Journal of Radiology and Nuclear Medicine, Vol 52, Iss 1, Pp 1-10 (2021)
institution DOAJ
collection DOAJ
language EN
topic FDG PET/CT
Colorectal carcinoma
Adjuvant chemotherapy
Medical physics. Medical radiology. Nuclear medicine
R895-920
spellingShingle FDG PET/CT
Colorectal carcinoma
Adjuvant chemotherapy
Medical physics. Medical radiology. Nuclear medicine
R895-920
Remon Zaher Elia
Rafik Abdelazem Elbastawessy
Hanaa Abdelkader Abdelmgeguid
Ahmed Mohamed Bassiouny
FDG PET/CT in follow UP patients with colorectal carcinoma after adjuvant chemotherapy
description Abstract Background 18F-2-fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography-computed tomography (PET-CT) is a method of imaging that assesses and measures metabolic avidity in cancer cells, acting as a proxy for underlying cellular activity and vitality and so providing anatomic and metabolic information. 18F-FDG PET-CT is beneficial for detecting local recurrence, distant metastases, and monitoring tumor viability after chemotherapy and radiotherapy in patients with colorectal cancer. Strict adherence to set protocols, technological processes, and good patient preparation are essential to produce the greatest results. The goal of the trial was to see how useful PET/CT was in following up on patients who had resected colorectal cancer and had completed adjuvant chemotherapy rounds. Results In this study, PET/CT early detected hepatic deposits, pulmonary masses, bone deposits, and sizable LNs. PET/CT provided useful information and had a considerable impact on disease management, enabling the detection of recurrent disease as early as possible with high accuracy in assessment of therapeutic response. It detected viable residual tumor cells in operative bed scar, small metabolically active LNs, hepatic focal lesions, peritoneal deposits, pulmonary secondaries, and bone deposits avoiding unnecessary surgeries. Conclusion Because of its high accuracy in detection and capacity to identify recurrent illness, FDG-PET-CT imaging is effective in evaluating post-therapeutic colorectal cancer patients with suspected tumor recurrence or distant metastases.
format article
author Remon Zaher Elia
Rafik Abdelazem Elbastawessy
Hanaa Abdelkader Abdelmgeguid
Ahmed Mohamed Bassiouny
author_facet Remon Zaher Elia
Rafik Abdelazem Elbastawessy
Hanaa Abdelkader Abdelmgeguid
Ahmed Mohamed Bassiouny
author_sort Remon Zaher Elia
title FDG PET/CT in follow UP patients with colorectal carcinoma after adjuvant chemotherapy
title_short FDG PET/CT in follow UP patients with colorectal carcinoma after adjuvant chemotherapy
title_full FDG PET/CT in follow UP patients with colorectal carcinoma after adjuvant chemotherapy
title_fullStr FDG PET/CT in follow UP patients with colorectal carcinoma after adjuvant chemotherapy
title_full_unstemmed FDG PET/CT in follow UP patients with colorectal carcinoma after adjuvant chemotherapy
title_sort fdg pet/ct in follow up patients with colorectal carcinoma after adjuvant chemotherapy
publisher SpringerOpen
publishDate 2021
url https://doaj.org/article/6be02219bbee4a4891037b8bb6c43ac9
work_keys_str_mv AT remonzaherelia fdgpetctinfollowuppatientswithcolorectalcarcinomaafteradjuvantchemotherapy
AT rafikabdelazemelbastawessy fdgpetctinfollowuppatientswithcolorectalcarcinomaafteradjuvantchemotherapy
AT hanaaabdelkaderabdelmgeguid fdgpetctinfollowuppatientswithcolorectalcarcinomaafteradjuvantchemotherapy
AT ahmedmohamedbassiouny fdgpetctinfollowuppatientswithcolorectalcarcinomaafteradjuvantchemotherapy
_version_ 1718372077592903680